Coherus Biosciences Inc (CHRS) USD0.0001
1.26%- This stock can be held in a
Stocks and Shares ISA
$0.02
(1.98%)$0.02
(1.98%)Company Information
About this company
Coherus BioSciences, Inc. is a commercial-stage oncology company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its commercial product, LOQTORZI (toripalimab-tpzi), is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in three ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a cytolytic anti-CCR8 antibody which is in Phase I study in patients with advanced solid tumors. CHS-1000 is a humanized Fc-modified IgG1 monoclonal antibody targeting ILT4.
Key people
Key facts
- EPICCHRS
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS19249H1032
- Market cap$128.65m
- Employees228
- Shares in issue115.90m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.